ReviewWorld journal of gastrointestinal oncology2021
Biomarkers for hepatocellular carcinoma based on body fluids and feces.
Review in World journal of gastrointestinal oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Trajectory-Based Integration of Biomarker Dynamics and Clinical Features for Prognostic Prediction in Hepatocellular Carcinoma: A Retrospective Cohort Study.Journal of hepatocellular carcinoma · 2026Article
- Article
- Clinical Outcomes of AFP-Negative Patients with Advanced HCC: A Propensity-Matched Analysis from a Retrospective Cohort Study.Journal of hepatocellular carcinoma · 2025Article
- Article
- Prognostic Value of Serum α-Fetoprotein Level as an Important Characteristic of Tumor Biology for Patients Undergoing Liver Resection of Early-Stage Hepatocellular Carcinoma (BCLC Stage 0/A): A Large Multicenter Analysis.Annals of surgical oncology · 2024Article
- Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options.Cell adhesion & migration · 2023Review
- The Performance of GALAD Score for Diagnosing Hepatocellular Carcinoma in Patients with Chronic Liver Diseases: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023Review
- Review
- Exosomes as mediators of tumor immune escape and immunotherapy in hepatocellular carcinoma.Liver research (Beijing, China) · 2022Review
- Critical biomarkers of hepatocellular carcinoma in body fluids and gut microbiota.World journal of gastrointestinal oncology · 2021Article
- Hepatocellular carcinoma biomarkers, an imminent need.World journal of gastrointestinal oncology · 2021Article
- Assessing the Predictive Accuracy of the aMAP Risk Score for Hepatocellular Carcinoma (HCC): Diagnostic Test Accuracy and Meta-analysis.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Novel non-/minimally-invasive and effective approaches are urgently needed to supplement and improve current strategies for diagnosis and management of hepatocellular carcinoma (HCC). Overwhelming evidence from published studies on HCC has documented that multiple molecular biomarkers detected in body fluids and feces can be utilized in early-diagnosis, predicting responses to specific therapies, evaluating prognosis before or after therapy, as well as serving as novel therapeutic targets. Detection and analysis of proteins, metabolites, circulating nucleic acids, circulating tumor cells, and extracellular vesicles in body fluids (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.